Literature DB >> 8563752

Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias.

T Nakamura1, D A Largaespada, J D Shaughnessy, N A Jenkins, N G Copeland.   

Abstract

Retroviruses induce myeloid leukaemia in BXH-2 mice by the insertional mutation of cellular proto-oncogenes or tumour suppressor genes. Disease genes can thus be identified by proviral tagging through the identification of common viral integration sites in BXH-2 leukaemia. Here, we describe a new approach for proviral tagging that greatly facilitates the identification of BXH-2 leukaemia genes. Using this approach, we identify three genes whose expression is activated by proviral integration in BXH-2 leukaemias; Hoxa7, Hoxa9, and a Pbx1-related homeobox gene, Meis1. Proviral activation of Hoxa7 or Hoxa9 is strongly correlated with proviral activation of Meis1 implying that Hoxa7 and Hoxa9 cooperate with Meis1 in leukaemia formation. These studies provide the first genetic evidence that Pbx1-related genes cooperate with Hox genes in leukaemia formation and identify a number of new murine myeloid leukaemia genes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8563752     DOI: 10.1038/ng0296-149

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  98 in total

1.  PBX and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins.

Authors:  K Shanmugam; N C Green; I Rambaldi; H U Saragovi; M S Featherstone
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells.

Authors:  W F Shen; S Rozenfeld; A Kwong; L G Köm ves; H J Lawrence; C Largman
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation.

Authors:  Mi Cai; Ellen M Langer; Jennifer G Gill; Ansuman T Satpathy; Jörn C Albring; Wumesh KC; Theresa L Murphy; Kenneth M Murphy
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

4.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

5.  CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein.

Authors:  Yue Zhang; Giovanni Morrone; Jianxuan Zhang; Xiaoai Chen; Xiaoling Lu; Liang Ma; Malcolm Moore; Pengbo Zhou
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

6.  Engrailed cooperates with extradenticle and homothorax to repress target genes in Drosophila.

Authors:  Masatomo Kobayashi; Miki Fujioka; Elena N Tolkunova; Deepali Deka; Muna Abu-Shaar; Richard S Mann; James B Jaynes
Journal:  Development       Date:  2003-02       Impact factor: 6.868

7.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors:  Paul M Ayton; Michael L Cleary
Journal:  Genes Dev       Date:  2003-09-02       Impact factor: 11.361

8.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

9.  An endocrine-exocrine switch in the activity of the pancreatic homeodomain protein PDX1 through formation of a trimeric complex with PBX1b and MRG1 (MEIS2).

Authors:  G H Swift; Y Liu; S D Rose; L J Bischof; S Steelman; A M Buchberg; C V Wright; R J MacDonald
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.